Dec 12, 2018 Proposed ‘Sunshine’ legislation pending in Italy By Mark Franklin Following the 2010 adoption of the US ‘Sunshine Act’, several EU member states have recently introduced statutory obligations for life...
Dec 03, 2018 Imagining new pricing models for cell and gene therapies in the EU By Marco de Morpurgo Cell and gene therapies are emerging at full speed, showing the potential to transform the future of medicine, but traditional pricing...
Nov 06, 2018 Is wearable data clinical grade and does it matter? By Mark Franklin Fantastic panel session at FT Global Pharmaceutical and Biotechnology on “Big data, big deal”. The questions on data are still questions,...
Nov 02, 2018 BREXIT and the impact on the Life Sciences industry By Caroline Scott With trade terms still unfinalised, stockpiling of medicines and the sourcing of alternative transportation and routes has become a...
Oct 17, 2018 UK plays catch-up in medicinal cannabis market By Robert Newman 1 November 2018 marks a turning point in relation to the use of medicinal cannabis in the UK. The Misuse of Drugs (Amendments) (Cannabis...
Aug 15, 2018 Duplicate marketing authorisations - EC consultation closes 10 September 2018 By Caroline Scott Ordinarily only one market authorisation is granted to an applicant for a specific medicinal product, however the applicant/holder can...
Jul 18, 2018 The Biomedical Bubble debate By Robert Newman The FT commented earlier today on the highly provocative report "The Biomedical Bubble" published by Nesta, the charity which, in its own...
Jul 12, 2018 Was the acquisition of PillPack inevitable and a sign of what is to come? By Robert Newman Two weeks after a certain tech giant announced its reported $1 billion acquisition of PillPack, I consider whether this move by the...
May 11, 2018 Government must do more to implement the Life Sciences Industrial Strategy By Robert Newman If anyone wondered why have a two-house system of parliament, perhaps a good starting point would be to read the opinion of the Science...
Apr 27, 2018 Reflecting on the Med-Tech Innovation Expo 2018 By Robert Newman Being 'sent to Coventry' is not ordinarily something one wants to hear, but at the end of April for the last few years I have made my...
Apr 12, 2018 Life after Brexit for UK science? By Robert Newman Reading this article by Clive Cookson at the FT, one can't help but experience differing emotions. Initially, you feel a sense of...
Apr 05, 2018 The Consero IP Forum for Life Sciences: a great opportunity for sharing knowledge By Roberto Valenti Between 9 and 11 April I will be in Basilea with Johan Renes from DLA Piper Amsterdam and Paula Gonzalez from DLA Piper Madrid at the...
Mar 28, 2018 Online vs Community pharmacies By Robert Newman It is going to be interesting to watch the continued tussle between the online and community pharamacy sectors. Both offer convincing...
Mar 22, 2018 Consolidation is the name of the game for our public healthcare system By Caroline Scott Very interesting article about the vision of the NHS to transform and consolidate our public healthcare system to drive further...
Mar 21, 2018 Webinar discussing the fallout from the up coming EU summit and what it may mean to businesses in areas such as the Life Sciences. By Mark Franklin Join members of DLA Piper's Brexit Committee for a webinar hosted right after this weeks EU summit ends. They will cut through the noise...
Mar 19, 2018 Some Brexit clarity.....to end of 2020 By DLA Piper A Brexit transition period to 31 December 2020 is good news for the Life Sciences industry. Brexit negotiators have now agreed Article...